Metsera Inc. Receives Mixed Ratings from Analysts Amid Market Activity

Metsera Inc. (NASDAQ:MTSR) has been assigned a consensus rating of “Hold” by analysts as the company navigates recent market fluctuations. According to Marketbeat Ratings, out of the eight analysts covering Metsera, one has issued a sell rating, three have recommended holding the stock, and four have given it a buy rating. The average twelve-month target price set by these analysts stands at $55.75.

Several equities analysts have recently provided insights on Metsera’s stock. On September 3, 2023, Cantor Fitzgerald reaffirmed an “overweight” rating for Metsera. On October 1, 2023, Wall Street Zen upgraded the stock from a “sell” to a “hold” rating. Additionally, on August 28, 2023, Bank of America raised its target price for Metsera from $45.00 to $50.00, maintaining a “buy” rating. Conversely, on September 30, 2023, Wells Fargo & Company downgraded Metsera from an “overweight” to an “equal weight” rating, setting a price target of $54.00. Leerink Partners also adjusted their stance, moving from a “strong-buy” to a “hold” rating on September 24, 2023.

Investor Activity and Stock Performance

In recent weeks, large investors have shown significant activity regarding Metsera’s shares. Legal & General Group Plc increased its holdings by 1.1% during the third quarter, now owning 23,491 shares valued at approximately $1,229,000. Osaic Holdings Inc. boosted its stake by 45.5% in the second quarter, owning 946 shares worth $27,000 after acquiring an additional 296 shares. Meanwhile, the Swiss National Bank raised its holdings by 1.5% in the third quarter, now possessing 40,700 shares valued at $2,130,000.

Additionally, BNP Paribas Financial Markets doubled its investment in Metsera during the second quarter, growing their holdings to 1,600 shares worth $46,000. Caitong International Asset Management Co. Ltd acquired a new stake in Metsera during the third quarter, valued at around $44,000.

Metsera’s stock opened at $70.50 on October 2, 2023, with a 50-day moving average of $62.33 and a two-hundred-day moving average of $43.97. The company currently holds a market capitalization of $7.42 billion and a price-to-earnings ratio of -11.16. Over the past year, Metsera has seen significant price fluctuations, with a low of $12.30 and a high of $83.86.

Quarterly Earnings Update

Metsera announced its quarterly earnings on November 12, 2023, reporting earnings per share (EPS) of ($1.11), which fell short of the consensus estimate of ($0.56) by $0.55. This underperformance may contribute to the varied analyst ratings and investor sentiment surrounding the stock.

Metsera, Inc. is a clinical stage biopharmaceutical company focused on developing next-generation injectable and oral nutrient-stimulated hormone analog peptides aimed at treating obesity and related conditions. Its product pipeline includes several candidates, notably MET-097i, MET-233, and MET-224o. As the company continues to evolve, the market will be closely watching for updates regarding its product developments and financial performance.